Rheumatoid Arthritis Therapeutics: Market Trends and R&D Insights

Table of Contents

1. Executive Summary

• 1.1 Scope and Methodology
• 1.2 Market Growth
• 1.3 Market Trends

2. Rheumatoid Arthritis: Scientific Background

• 2.1 Disease Overview
• 2.2 Etiology of Rheumatoid Arthritis
  • 2.2.1 Genetic Factors
• 2.3 The Immune Response
  • 2.3.1 Cytokines
  • 2.3.2 Helper T-Cells and RA
  • 2.3.3 Leukocytes
• 2.4 Symptoms
• 2.5 Diagnosis
  • 2.5.1 Diagnostic Criteria
    • 2.5.1.1 Blood/Serum Tests
    • 2.5.1.2 Markers
    • 2.5.1.3 Imaging
• 2.6 Risk Factors

3. The Financial and Demographic Impact of Rheumatoid Arthritis

• 3.1 The Prevalence and Incidence of Rheumatoid Arthritis
  • 3.1.1 Worldwide
  • 3.1.2 US
• 3.2 The Financial Impact of Rheumatoid Arthritis

4. Current Treatment Options for Rheumatoid Arthritis

• 4.1 NSAIDs
• 4.2 Corticosteroids
• 4.3 DMARDs
• 4.4 Biological Response Modifiers
  • 4.4.1 Key Biological Response Modifiers
    • 4.4.1.1 Remicade
    • 4.4.1.1.1Clinical Efficacy and Dosage
    • 4.4.1.2 Enbrel
    • 4.4.1.2.1Clinical Efficacy and Dosage
    • 4.4.1.3 Humira
    • 4.4.1.3.1Clinical Efficacy and Dosage
    • 4.4.1.4 Kineret
    • 4.4.1.4.1Clinical Efficacy and Dosage
    • 4.4.1.5 Orencia
    • 4.4.1.5.1Clinical Efficacy and Dosage
    • 4.4.1.6 Rituxan
    • 4.4.1.6.1Clinical Efficacy and Dosage
• 4.5 Surgical Treatments

5. Major Issues Affecting the RA Market

• 5.1 How are the Biological Response Modifiers Changing the Face of RA Therapy?
• 5.2 With What Drugs Are the Biological Response Modifiers Competing?
• 5.3 The High Cost of RA Biologics
• 5.4 Medicare Reform in the US: Impact on RA Market
  • 5.4.1 Medicare Self-Injectable Demo Project: A Challenge to Remicade
  • 5.4.2 The New Prescription Drug Bill's Impact on RA Therapy Competition

6. The Global Market for RA Therapies

• 6.1 Commercial Market Size
  • 6.1.1 US Revenues
  • 6.1.2 Non-US Revenues
• 6.2 Key Products Driving Growth
  • 6.2.1 Remicade: Market Position and Revenues
  • 6.2.2 Enbrel: Market Position and Revenues
  • 6.2.3 Humira: Market Position and Revenues
  • 6.2.4 Kineret: Market Position and Revenues
  • 6.2.5 Orencia: Market Position and Revenues
  • 6.2.6 Rituxan: Market Position and Revenues
• 6.3 Market Share
  • 6.3.1 Product
  • 6.3.2 Country/Region

7. The R&D Pipeline for RA Therapies

• 7.1 Unmet Need
• 7.2 Key Clinical Trial Endpoints
• 7.3 R&D Trends in RA Therapy
• 7.4 Phase III Products Nearing Approval
  • 7.4.1 Cimzia (CDP-870)
    • 7.4.1.1 Clinical Efficacy
    • 7.4.1.2 Market Assessment
  • 7.4.2 Actemra
    • 7.4.2.1 Clinical Efficacy
    • 7.4.2.2 Market Assessment
  • 7.4.3 CellCept
    • 7.4.3.1 Clinical Efficacy
    • 7.4.3.2 Market Assessment
  • 7.4.4 CNTO 148
    • 7.4.4.1 Clinical Efficacy
    • 7.4.4.2 Market Assessment
• 7.5 Selected Phase II Products in Development
  • 7.5.1 AMG 714
  • 7.5.2 HuMax-CD 20
  • 7.5.3 R1594
  • 7.5.4 Eculizumab
  • 7.5.5 AMG 108
  • 7.5.6 Denosumab
  • 7.5.7 P38 MAP Kinase Inhibitor
  • 7.5.8 BMS 561392
  • 7.5.9 Lymphostat-B
  • 7.5.10 VX 702

8. The Financial Outlook of the RA Therapy Market

• 8.1 Financial Forecasts for Key Products
  • 8.1.1 Remicade
  • 8.1.2 Enbrel
  • 8.1.3 Humira
  • 8.1.4 Orencia
  • 8.1.5 Rituxan
• 8.2 Overall Market Forecast for RA Market 2006-2011

Tables

• Table 3.1 Prevalence of Chronic Conditions Causing Disabilities
• Table 5.1 Approved DMARDs for Rheumatoid Arthritis
• Table 5.2 Profiles of the Leading DMARDs and BRMs
• Table 5.3 Out-of-Pocket Costs Associated with Demonstration Drug Project
• Table 6.1 Sales of Key BRMs for Rheumatoid Arthritis, 2000-2006
• Table 6.2 US Sales of Leading RA Therapies 2000-2006
• Table 6.3 Non-US Sales of Leading RA Therapies 2000-2006
• Table 6.4 Sales of Remicade 2000-2006, US, Japan, Europe + Rest of World
• Table 6.5 Global Sales of Enbrel, US & Canada, Rest of World 2000-2006
• Table 6.6 Global Sales of Humira, US, Rest of World 2003-2006
• Table 7.1 New Rheumatoid Arthritis Drugs in Development
• Table 8.1 RA Therapy Market Financial Forecast 2006-2011

Graphs

• Graph 3.1 Prevalence of RA in Various Countries
• Graph 6.1 Global Sales of Leading RA Therapies 2000-2005, by product
• Graph 6.2 US Sales of Leading RA Therapies 2000-2005, by product
• Graph 6.3 Non-US Sales of Leading RA Therapies 2000-2005, by product
• Graph 6.4 Remicade Market Share, by Country/Region 2005
• Graph 6.5 Enbrel Market Share, by Country/Region 2005
• Graph 6.6 Humira Market Share, by Country/Region 2005
• Graph 6.7 Global Market Share of Leading RA Therapies by Product, 2005
• Graph 6.8 US Market Share of Leading RA Therapies by Product, 2005
• Graph 6.9 Non-US Market Share of Leading RA Therapies by Product, 2005
• Graph 6.10 RA Therapy Market Share, by Country/Region 2005
• Graph 8.1 Sales Forecast for Remicade 2006-2011
• Graph 8.2 Sales Forecast for Enbrel 2006-2011
• Graph 8.3 Sales Forecast for Humira 2006-2011
• Graph 8.4 Sales Forecast for Orencia 2006-2011
• Graph 8.5 Sales Forecast for Rituxan 2006-2011

Diagrams

• Diagram 4.1 Rheumatoid Arthritis Treatment Guidelines
• Diagram 4.2 The American College of Rheumatology Criteria (ACR) Criteria